Skip to content

The effects of multiple doses of intravenous tranexamic acid on postoperative blood loss, coagulation, and knee function in patients undergoing ACL reconstruction

The effects of multiple doses of intravenous tranexamic acid on postoperative blood loss, coagulation, and knee function in patients undergoing ACL reconstruction

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022349
Enrollment
Unknown
Registered
2019-04-07
Start date
2019-04-07
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACL reconstruction

Interventions

B:IV 20mg/kg TXA before tourniquet release, and 1 g TXA after 3h postoperatively
D:IV 20mg/kg TXA before tourniquet release, and 1 g TXA after 3h and 6h postoperatively

Sponsors

Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The patients undergoing ACL reconstruction; (2) Normal platelet and coagulation function preoperatively; (3) Normal intravenous ultrasound in the lower extremities preoperatively; (4) To be able to and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Systemic infections such as pulmonary infection or urinary tract infection are not controlled preoperatively; (2) Abnormal immune function or combined immune-related disease preoperatively; (3) Abnormal inflammatory index preoperatively (C-reactive protein >20 mg/L); (4) Abnormal fibrinolysis index preoperatively (FDP > 5mg/L); (5) Discontinuation of oral anticoagulants or aspirin less than 1 week; (6) Allergy to tranexamic acid (TXA) or dexamethasone or have contraindications; (7) Patients at high risk of thrombosis; (8) History of deep vein thrombosis (VTE, calf muscle vein thrombosis or superficial vein thrombosis, pulmonary embolism); (9) serious liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Blood loss;

Secondary

MeasureTime frame
Hb;Hct;DVT, PE;Transfusion;Swelling;VAS pain score;color Doppler Ultrasonic (CDU) examination in lower extremity;ROM;IKDC;Lysholm;Muscle strength;Coagulation index;Drainage;Satisfaction scores;Complications;hemarthrosis;Aspiration;

Countries

China

Contacts

Public ContactJian Li

West China Hospital, Sichuan University

18980601388@163.com+86 18980601388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026